These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 2334902)

  • 1. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
    Biddle WC; Pancook J; Goldrosen M; Han T; Foon KA; Vaickus L
    Cancer Res; 1990 May; 50(10):2991-6. PubMed ID: 2334902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
    Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
    J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo.
    Gill I; Agah R; Hu E; Mazumder A
    Cancer Res; 1989 Oct; 49(19):5377-9. PubMed ID: 2788499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
    Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
    Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon gamma augments Lym-1-dependent, granulocyte-mediated tumor cell lysis.
    Vaickus L; Biddle W; Cemerlić D; Foon KA
    Blood; 1990 Jun; 75(12):2408-16. PubMed ID: 2140949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system.
    Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL
    Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2.
    Morgan AC; Sullivan W; Graves S; Woodhouse CS
    Cancer Res; 1989 May; 49(10):2773-6. PubMed ID: 2785437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
    de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
    Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
    Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
    Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
    J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
    Munn DH; Cheung NK
    Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
    Christiaansen JE; Sears DW
    Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent sensitivity of human K lymphocytes to the spatial orientation and organization of target cell-bound antibodies as measured by the efficiency of antibody-dependent cellular cytotoxicity (ADCC).
    Christiaansen JE; Burnside SS; Sears DW
    J Immunol; 1987 Apr; 138(7):2236-43. PubMed ID: 3549899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
    Woodhouse CS; Morgan AC
    Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effector characteristics of the IgG3 murine monoclonal antibody 113F1.
    Weiner LM; Zarou CM; O'Brien J; Ring D
    J Biol Response Mod; 1989 Jun; 8(3):227-37. PubMed ID: 2787391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of alemtuzumab on neoplastic B cells.
    Golay J; Manganini M; Rambaldi A; Introna M
    Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-class II antibodies in AIDS patients and AIDS-risk groups.
    de la Barrera S; Fainboim L; Lugo S; Picchio GR; Muchinik GR; de Bracco MM
    Immunology; 1987 Dec; 62(4):599-604. PubMed ID: 3501399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.